Surgical issues surrounding use of aromatase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 97-103

  Dixon, J Michael ^a   Renshaw, Lorna ^a   Murray, Juliette ^a   Macaskill, E Jane ^a   Young, Oliver ^a   Miller, William R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Neoadjuvant; Surgical outcomes

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; ENDOCRINE FUNCTION; HISTOLOGY; HORMONAL THERAPY; HUMAN; MASTECTOMY; METASTASIS; POSTMENOPAUSE; POSTOPERATIVE CARE; PREDICTION; PROTEIN EXPRESSION; RECURRENCE RISK; SURGICAL TECHNIQUE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 23744433275     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.04.024     Document Type: Conference Paper

References (25)

1. H.D. Bear Indications for neoadjuvant chemotherapy for breast cancer Semin. Oncol. 25 2 Suppl. 3 1998 3 12
2. M. Perloff, and G.J. Lesnick Chemotherapy before and after mastectomy in stage III breast cancer Arch. Surg. 117 7 1982 879 881
3. P. Schick, J. Goodstein, J. Moor, J. Butler, and K.L. Senter Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer J. Surg. Oncol. 22 4 1983 278 282
4. J.M. Dixon, T.J. Anderson, and W.R. Miller Neoadjuvant endocrine therapy of breast cancer: a surgical perspective Eur. J. Cancer 38 17 2002 2214 2221
5. J.M. Dixon Neoadjuvant therapy in postmenopausal women J.N. Ingle M. Dowsett Advances in Endocrine Therapy of Breast Cancer: Procedures of the 2003 Gleneagles Conference 2004 Summit Communications New York 73 85
6. W. Eiermann, S. Paepke, and J. Appfelstaedt Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann. Oncol. 12 11 2001 1527 1532
7. I. Smith, M. Dowsett on behalf of the IMPACT Trialists Comparison of anastrozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial Breast Cancer Res. Treat. 82 supp 1 2003 S6
8. L. Cataliotti, on behalf of the PROACT trialists, Efficacy of Preoperative Anastrozole Compared with Tamoxifen in postmenopausal women with hormone receptor positive breast cancer, Presented at 4th European Breast Cancer Conference Hamburg, Germany, 17 March 2004.
9. V.F. Semiglazov, V.V. Semiglazov, and V.G. Ivanov Neoadjuvant endocrine therapy: exemestane (E) versus tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4, N1-2, M0) Breast Cancer Res. Treat. 82 supp 1 2003 S22
10. M.J. Ellis, A. Coop, and B. Singh Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J. Clin. Oncol. 19 18 2001 3808 3816
11. J.M. Horobin, P.E. Preece, J.A. Dewar, R.A.B. Wood, and A. Cushieri Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only Br. J. Surg. 78 2 1991 213 217
12. J.M. Dixon, C.D. Love, and C.O. Bellamy Letrozole as primary medical therapy for locally advanced and large operable breast cancer Breast Cancer Res. Treat. 66 3 2001 191 199
13. J.M. Dixon, L. Renshaw, C. Bellamy, M. Stuart, G. Hoctin-Boes, and W.R. Miller The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study Clin. Cancer Res. 6 6 2000 2229 2235
14. J.M. Dixon, T. Anderson, and W.R. Miller Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer Proc. Am. Soc. Clin. Oncol. 20 2001 40b (Abstract 1908)
15. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
16. P.E. Goss, J.N. Ingle, and S. Martino A Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N. Engl. J. Med. 349 2003 1793 1802
17. J.C. Keen, J.M. Dixon, and E.P. Miller The expression of KiS1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer Breast Cancer Res. Treat. 44 2 1997 123 133
18. W.R. Miller, T.J. Anderson, R.A. Hawkins, J. Keen, and J.M. Dixon Neoadjuvant endocrine treatment: the Edinburgh experience A. Howell M. Dowsett Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects vol. 4 1999 Elsevier Science B.V. Amsterdam 89 99
19. O. Young, J. Murray, and L. Renshaw Neoadjuvant letrozole is equally effective in HER2 positive and negative breast cancers Breast Cancer Res. Treat. 88 supp 1 2004 S38
20. J.M. Dixon, J. Jackson, and M. Hills Anastrozole demonstrates clinical and biological effectiveness in erbB2 ER positive breast cancers Eur. J. Cancer 40 18 2004 2742 2747
21. J. Bradbeer, and J. Kyngdon Primary treatment of breast cancer in elderly women with tamoxifen Clin. Oncol. 9 1 1983 31 34
22. L. Renshaw, J. Murray, and D. Cameron Is there an optimal duration of neoadjuvant therapy? Breast Cancer Res. Treat. 88 supp 1 2004 S36
23. U. Veronesi, G. Bonadonna, and S. Zurrida Conservation surgery after primary chemotherapy in large carcinomas of the breast Ann. Surg. 222 5 1995 612 618
24. A. Makris, T.J. Powles, and S.E. Ashley A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann. Oncol. 9 11 1998 1179 1184
25. P. Ellis, S. Ashley, and G. Walsh Identification of clinical factors predicting outcome following primary chemotherapy for operable breast cancer Breast 8 1999 235